12171
clinical study

Retrospective Evaluation of an Artificial Intelligence (AI) System for Enhanced Detection of Pulmonary Embolism and Potential Clinical Impact Using Chart Review

Materials & Methods

This study evaluated the effectiveness of integrating artificial intelligence into the diagnosis of pulmonary embolism (PE) using CT angiograms (CTA). The goal was to identify PE cases that might be overlooked by radiologists, assess how AI could improve detection rates and explore the potential impact on patient care.

Results

Analyzing 1,471 CTAs using the Aidoc AI algorithm, detection rates of AI and radiologists were compared. Discrepancies between the two were reviewed by a panel of two thoracic radiologists. The results revealed that radiologists initially detected PE in 10.1% of cases, while AI identified PE in 11.7% of cases, including 10 additional cases missed by radiologists. This led to a 6.8% enhanced triage rate. Notably, all missed PEs were smaller segmental or subsegmental, and no central PEs were overlooked. Further review of patient charts found no negative clinical outcomes or subsequent PE diagnoses associated with these missed cases.

Conclusions

The findings suggest that AI can help radiologists significantly improve PE awareness and potentially enhance patient outcomes, though further research with follow-up imaging may provide more insights into the clinical impact of missed diagnoses.

Explore the Latest AI Insights, Trends and Research

Amalia Schreier

<p>Amalia Schreier serves as the Senior Vice President of Regulatory Affairs and Legal at Aidoc, guiding our company and product’s regulatory strategies and ensuring alignment with AI-focused medical device compliance requirements. Since her tenure began, she has streamlined our FDA clearance processes, emphasizing a meticulous approach that underscores our commitment to product and clinical quality.</p> <p>With a solid foundation from her legal background and leadership role in AI startup regulatory departments, Schreier brings invaluable insights and expertise to our regulatory framework. Prior to her tech world experience, she worked as a human-rights lawyer and legal policy scholar, with a BA and LLM in law from the Hebrew University of Jerusalem.</p>

Deepak Srikant

<p>Deepak Srikant is a global marketing executive with over 20 years of experience, specializing in the commercialization of medical devices and digital health solutions. He has a proven track record in driving growth, having led successful go-to-market strategies, product launches and market expansions across the U.S. and EMEA.</p> <p>Srikant’s expertise extends to upstream and downstream marketing, professional education and sales enablement. His leadership at companies such as Silk Road Medical (acquired by Boston Scientific) and Aptus Endosystems (acquired by Medtronic) has consistently resulted in revenue growth, enhanced customer retention and successful product adoption.</p> <p>Srikant holds an MBA from the Yale School of Management and a bachelor’s degree in mechanical engineering from Rensselaer Polytechnic Institute. Currently, he leads product marketing for Aidoc’s cardiovascular service line.</p>

Laci Costa

<p>Laci Costa is the Director of Neurovascular Product Marketing at Aidoc. She leads marketing and commercial strategy for the neuro AI portfolio of products. She has 16 years of experience working in the medical device and healthcare industry, with over 12 years dedicated to neurovascular solutions.</p> <p>Costa’s known for her expertise in the neurovascular industry, go-to-market experience with new technologies and upstream and downstream product marketing leadership. She’s held various leadership positions in product marketing, clinical education and professional affairs spanning across start-up organizations to large publicly traded companies.</p> <p>Costa holds a bachelor’s degree in psychology from the University of Oklahoma and an MBA from USC Marshall School of Business.</p>